Scribe Therapeutics

Scribe is enabling the creation of genetic medicines through its CRISPR by Design™ approach to genetic modification.

Research Alameda, United States ~86 employees Private · Series B

Work at Scribe Therapeutics in HR or recruiting? Claim this page

Employees
86
-2.3% in the 3 months to Sep 2026
Revenue / employee
$29.1K
Revenue ~$2.5M
Total funding
$120M
Last round Series B, Mar 2021
12-month attrition
27.2%
Tech: 22.5%
H1B filings, FY2025
2
Sponsors visas

Headcount trend

Scribe Therapeutics went from 128 employees in Oct 2024 to 86 in Sep 2026. Apr to Sep 2026: 3 people joined, 7 left.

Funding rounds

Total funding$120M
Funding rounds3
Investors8

Org structure

Headcount by department

Other62
Finance8
Operations6
HR3
Engineering3
Sales2
Marketing1
Success1

H-1B sponsorship

H-1B Sponsorship Limited
H-1B Filings by Department
Engineering8

The department split adds up all the years listed above. FY2025 alone: 2 filings.

Peer reviews

Worked with someone at Scribe Therapeutics?

Anonymous peer reviews on OffTheRecord

Read or write a review

Similar companies

Scribe Therapeutics FAQ

How many employees does Scribe Therapeutics have?

Scribe Therapeutics has about 86 employees, down 2.3% over the 3 months to Sep 2026.

Does Scribe Therapeutics sponsor H1B visas?

Yes. Scribe Therapeutics filed 2 H1B (LCA) applications in FY2025, according to the latest U.S. Department of Labor disclosures. Most of them were for Engineering roles.

What is Scribe Therapeutics's revenue per employee?

Scribe Therapeutics makes about $29K in revenue per employee, based on $2.5M annual revenue and 86 employees.

How much funding has Scribe Therapeutics raised?

Scribe Therapeutics has raised $120M in total funding; its latest round was Series B in Mar 2021.

Data from Company Prospectus, DOL LCA disclosures, WARN notices and 6figr salary profiles.